타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Humira (adalimumab) |
Overview Company | AbbVie |
Overview Modality | ANTIBODY |
Overview Target | TNF-α |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | novel object recognition test |
Positioning Known limitation | Anti-drug antibodies, TNF-independent inflammation, and immunogenicity lowering trough levels. |
MoA Mechanism | Adalimumab binds specifically to TNF-α and blocks its interaction with p55 and p75 cell-surface TNF receptors, neutralizing TNF-mediated inflammatory cascades (IL-6, adhesion molecules, acute-phase proteins). |
MoA Biomarker | CRP, ESR, disease-specific scores (DAS28, PASI, Mayo for IBD). |
Toxicology Species | Cynomolgus monkey |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. |
Toxicology CRS | N/A |
Clinical Safety signal | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Humira (adalimumab) |
Overview Company | AbbVie |
Overview Modality | ANTIBODY |
Overview Target | TNF-α |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | novel object recognition test |
Positioning Known limitation | Anti-drug antibodies, TNF-independent inflammation, and immunogenicity lowering trough levels. |
MoA Mechanism | Adalimumab binds specifically to TNF-α and blocks its interaction with p55 and p75 cell-surface TNF receptors, neutralizing TNF-mediated inflammatory cascades (IL-6, adhesion molecules, acute-phase proteins). |
MoA Biomarker | CRP, ESR, disease-specific scores (DAS28, PASI, Mayo for IBD). |
Toxicology Species | Cynomolgus monkey |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. |
Toxicology CRS | N/A |
Clinical Safety signal | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교